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028 The Journal of Thoracic and Cardbjective: The mechanisms contributing to ascending thoracic aortic aneurysms
ssociated with bicuspid aortic valves may differ from ascending thoracic aortic
neurysms with tricuspid aortic valves. Matrix metalloproteinases and their endog-
nous inhibitors have been causally linked to ascending thoracic aortic aneurysm
ormation. This study tested the hypothesis that specific and different matrix
etalloproteinase and tissue inhibitors of metalloproteinase profiles would be ob-
erved in ascending thoracic aortic aneurysm samples from patients with bicuspid
ortic valves versus tricuspid aortic valves.
ethods: Ascending thoracic aortic aneurysm samples taken from patients with
icuspid aortic valve (n 53) and patients with tricuspid aortic valve (n 46) were
ssessed for representative subtypes of all matrix metalloproteinase classes and
ll 4 known tissue inhibitors of metalloproteinases. Levels were compared
optical density units, median (interquartile range)] both to reference control
scending aortic samples (n  26) and within each valve group by aneurysm
iameter (3.9 cm, 4.0-5.9 cm and 6.0 cm).
esults: Different and specific matrix metalloproteinase and tissue inhibitors of
etalloproteinase profiles were observed in the ascending thoracic aortic aneurysm
roups. In bicuspid aortic valves, matrix metalloproteinase-2 increased by 34%
hen compared with either tricuspid aortic valves or control (P  .05), and
atrix metalloproteinase-14 decreased by 59% compared with tricuspid aortic
alves (P  .05). In tricuspid aortic valve samples, tissue inhibitors of metal-
oproteinase-2 decreased by 35% when compared with either tricuspid aortic
alves or control (P  .05), and matrix metalloproteinase-13 increased by 140%
n the 4.0- to 5.9-cm diameter range (P  .05).
onclusions: A unique matrix metalloproteinase and tissue inhibitor of metallopro-
einase portfolio was observed in ascending thoracic aortic aneurysms from patients
ith bicuspid aortic valve compared with patients with tricuspid aortic valve. These
ifferences, suggesting disparate mechanisms of extracellular matrix remodeling,
ay provide unique biochemical targets for ascending thoracic aortic aneurysm
rognostication and treatment in these 2 groups of patients.
istorically, research regarding the underlying basis for ascending thoracic
aortic aneurysm (ATAA) formation has been limited to Marfan’s syndrome
and other connective tissue disorders. More recently, interest has shifted to
he more common conditions associated with ATAAs.1-4 These include nonspecifi
edial degenerative disease associated with tricuspid aortic valves (TAVs) and
TAAs associated with congenital bicuspid aortic valves (BAVs).1-4 Recent work
as shown that differences between these 2 ATAA populations exist at both the
iovascular Surgery ● April 2007
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A
CDolecular and histologic level but that these differences
emain incompletely characterized.1-4 A central theme wit
egard to ATAA formation is disturbances in proteolytic
ctivity within the aneurysm wall.5-7 The matrix metallo-
roteinases (MMPs) constitute a large family of enzymes
hat process or degrade the extracellular matrix. The MMPs
re grouped into classes based on their primary substrate
pecificities. An association has been established between
ncreases in MMPs and development of aortic aneurysm5,6
rimary endogenous control of MMP activity is maintained
hrough 4 tissue inhibitors of metalloproteinases (TIMP7
n aortic aneurysms, imbalances in the ambient MMP and
IMP profiles within the aortic wall are observed that favor
et proteolysis.6
The possible contribution of changes in MMP and TIMP
rofiles within the aortic wall of ATAAs from patients with
AV has been incompletely quantified. Further, whether
nd to what degree these profiles differ from ATAAs from
atients with TAV is unknown. Accordingly, the present
tudy tested the hypothesis that specific differences exist
ith respect to the MMP and TIMP cassettes expressed in
TAAs in patients with BAV versus patients with TAV.
aterials and Methods
tudy Population
he study population consisted of ascending aortic specimens
rom 53 patients with BAV and 46 patients with TAV taken at the
ime of aneurysm resection or aortic valve replacement. A refer-
nce control group (n  26) was made up of ascending aortic
pecimens taken from 1 patient at coronary bypass, 14 heart
ransplant recipients, and 11 heart or lung donors. No patient
ad an aortic dissection, connective tissue disorder, or inflam-
atory aortic disease. For ascending aortic diameters less than
.0 cm, aortic resection was not performed but a biopsy was taken
rom the aortotomy site during aortic valve replacement. There
ere no gender differences between the groups (control: 76% men;
AV: 75% men; TAV: 59% men, P .14 2). The ages within the
roups were as follows: median (interquartile range): control, 52
18) years; BAV, 60 (14) years; TAV, 72 (15) years (P  .05
AV/TAV from control, TAV from BAV). The aortic diameters
median (interquartile range)] were not different between ATAA
roups but different from control: control, 2.8 (0.3) cm; BAV, 5.1
0.7) cm; TAV, 5.5 (1.6) cm (P  .05 BAV/TAV from control).
The study was approved by the Institutional Review Boards of
oth The Medical University of South Carolina and The University
Abbreviations and Acronyms
ATAA ascending thoracic aortic aneurysm
BAV  bicuspid aortic valve
MMP matrix metalloproteinase
TAV  tricuspid aortic valve
TIMP  tissue inhibitors of metalloproteinase
TNF  tumor necrosis factorf Pennsylvania. Informed consent was obtained from all patients. s
The Journal of Thoracicmmunoblotting and Zymography
Aortic sample preparations. The resected specimens were
laced in tubes and snap-frozen in a dry ice/methanol slurry prior
o storage at 80°C. For analysis, the samples were homogenized
n a cold acidic extraction buffer solution to prevent proteolytic
ctivation during the extraction process.8 The homogenate wa
hen centrifuged (4°C, 10 minutes, 1200g), the supernatant con-
entrated (Centriplus; Millipore, Bedford, Mass), and the final
rotein concentration of the aortic extracts was determined (BCA
rotein Assay; Pierce, Rockford, Ill).
Zymography. Relative aortic MMP gelatinase activity was ex-
mined by substrate-specific zymographic analysis as described
reviously.9 The aortic extracts (10 g total protein) were load
nto electrophoretic gels (sodium dodecylsulfate–polyacrylimide
el electrophoresis) containing 1 mg/mL of gelatin followed by
ashing and incubation in an MMP substrate buffer for 12 hours
t 37°C. After incubation, the gels were stained using 0.1% Coo-
assie blue and destained in water. An MMP-2/-9 recombinant
tandard (CC073, Chemicon, Temecula, Calif) was added to each
el to serve as a positive control.
Immunoblotting. The relative abundances of MMPs/TIMPs
ere examined by using quantitative immunoblotting tech-
iques.8,9 Briefly, 10 g of aortic extract was loaded onto a 4
2% Bis-Tris gradient gel (Invitrogen Corp, Carlsbad, Calif) and
ubjected to electrophoresis. The fractionated proteins were
ransferred to nitrocellulose membranes (0.45 m, Bio-Rad,
ercules, Calif) and subsequently blocked with 5% nonfat dry
ilk in phosphate-buffered saline solution (PBS) for 1 hour at
oom temperature. The membranes were incubated in diluted
ntiserum (0.4 g/mL in 5% nonfat dry milk/PBS) containing
pecific antibodies representative of all nongelatinase MMP
lasses (collagenases, elastases, stromelysins, matrilysins, and
he membrane-type MMPs) and all known TIMPs (see Appendix).
ollowing incubation with the primary antibody, the membranes
ere extensively washed (3  10 minutes, 25 mL PBS), and a
econdary peroxidase-conjugated antibody (species-dependent on
rimary antibody used) was applied (1:5000, 5% nonfat dry milk/
BS) and incubated for 1 hour at room temperature. Following
ashing (4  15 minutes, 25 mL PBS), immunoreactive signals
ere detected by briefly incubating the membranes with a chemi-
uminescent substrate (Western Lightning Chemiluminescence Re-
gent Plus, Perkin Elmer, Piscataway, NJ) and exposing the blot to
lm (Hyperfilm, GE Healthcare, Piscataway, NJ).
ata Analysis
he zymograms and immunoblot films were digitized and quanti-
ative image analysis (Gel Pro Analyzer; Media Cybernetics, Sil-
er Spring, Md) was performed.
All statistical procedures were performed using the Stata sta-
istical software package (Stata Corporation, College Station, Tex).
he analysis was conducted in 2 parts. For the first analysis, all
amples in the BAV and TAV groups with an ascending size less
han 4.0 cm were excluded. The MMP and TIMP data distributions
or the reference controls, BAV group, and TAV group were tested
or normality using the Shapiro–Wilk test. The results indicated
onparametricity, and hence a two-sample Mann–Whitney rank
um test was performed to test comparisons between groups.
and Cardiovascular Surgery ● Volume 133, Number 4 1029
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1
A
CDFor the second portion of the analysis, the raw data was
ategorized by ascending aortic size: 3.9 cm, 4.0-5.9 cm, and
6.0 cm. The 3.9-cm group was composed of all aortic samples
ith diameters3.9 cm across the 3 groups (26 reference controls,
BAVs, and 9 TAVs; n  38). Spearman’s rank correlation
oefficient testing was used to determine correlation between
scending aortic size as categorized and MMPs/TIMPs. Compar-
sons within the BAV and TAV groups were performed using a
wo-sample Mann–Whitney rank sum test.
Regression analyses were also performed testing for the
ffects of age, hypertension, aortic valve pathology (stenosis
ersus regurgitation), and aortic diameter indexed to body sur-
ace area.10
Data were calculated as a percentage of the reference control
roup set to a mean of 100% and expressed as the median (inter-
uartile range). As such, in the succeeding figures, the control
alues will deviate from 100 due to expression of the median, not
he mean, value.
esults
verall Analysis
he aortic samples were assayed for MMP species repre-
enting all of the known classes and are given in Ta
ith representative immunoblots and zymograms given in
igure 1. Within the gelatinase (MMP-2, MMP-9) cl
MP-2 was increased in the BAV group relative to the
AV and reference control groups, with no significant dif-
erences observed with MMP-9. In the membrane-type
MP class (MMP-14, MMP-15), MMP-14 was decreased
n the BAV group relative the TAV and reference control
alues. In the stromelysin/matrilysin (MMP-3, MMP-7)
ABLE 1. MMP and TIMP immunoblotting results (median
interquartile range])
Reference
Controls BAV TAV
Analyte (n  26) (n  50) (n  37)
ollagenases MMP-1 91 (117) 69 (49) 52 (49)
MMP-8 54 (78) 92 (90) 90 (86)
MMP-13 71 (144) 71 (109) 91 (300)
elatinases MMP-2 93 (86) 140 (77)* 92 (41)†
MMP-9 56 (99) 52 (65) 61 (100)
ysins MMP-3 67 (102) 41 (72) 43 (50)*
MMP-7 72 (105) 78 (116) 97 (227)
embrane type MMP-14 59 (66) 38 (61)* 92 (78)†
MMP-15 88 (57) 97 (58) 87 (66)
lastase MMP-12 80 (75) 80 (74) 67 (68)
nhibitors TIMP-1 67 (101) 59 (150) 98 (133)
TIMP-2 80 (42) 79 (49) 52 (37)*,†
TIMP-3 63 (130) 61 (96) 51 (126)
TIMP-4 80 (56) 76 (54) 104 (108)
MP, Matrix metalloproteinase; TIMP, tissue inhibitors of metalloprotein-
se; BAV, bicuspid aortic valve; TAV, tricuspid aortic valve. *P  .05 vs
eference control. †P  .05 vs BAV.lass, MMP-3 was decreased in the TAV group relative to c
030 The Journal of Thoracic and Cardiovascular Surgery ● Apr1,
ontrol values. No differences were observed in the colla-
enase (MMP-1, MMP-8, MMP-13) or elastase (MMP-12)
lasses.
In this study the aortic samples were surveyed for all
IMP subtypes. As shown in Table 1, TIMP-2 
ecreased in the TAV group relative to BAV group and
igure 1. Representative immunoblots and zymographic analysis
f the MMPs and TIMPs in reference control, BAV, and TAV
scending aortic samples. MMP, Matrix metalloproteinase;
IMP, tissue inhibitors of metalloproteinase; BAV, bicuspid aortic
alve; TAV, tricuspid aortic valve.ontrol values.
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A
CDize Analysis: BAV
n the BAV group, Spearman’s testing revealed weak but
ignificant correlations between MMP-2 (Figure 2, 
alue 0.243, P  .02) and MMP-14 (Figure 3, rho va
0.313, P  .003) and aneurysm size.
Examination by categorized size (Table 2) showed 
reased MMP-2 and decreased MMP-3 and MMP-14 in the
.0- to 5.9-cm diameter size range compared with the
3.9-cm group. TIMP-1 was decreased in the 6.0-cm size
ange relative to the 3.9-cm group.
igure 2. Comparison of MMP-2 levels for BAV and TAV aneu-
ysms by aneurysm size. MMP-2 was increased in the medium
AV aneurysm group relative to the small BAV aneurysm group.
MP, Matrix metalloproteinase; BAV, bicuspid aortic valve; TAV,
ricuspid aortic valve.
igure 3. Comparison of MMP-14 levels for BAV and TAV aneu-
ysms by aneurysm size. In the BAV cohort, MMP-14 decreased in
he medium aneurysm group compared with the small aneurysm
roup. MMP, Matrix metalloproteinase; BAV, bicuspid aortic
alve; TAV, tricuspid aortic valve. v
The Journal of Thoracicize Analysis: TAV
n the TAV group, Spearman’s testing revealed significant
orrelations between MMP-7 (Figure 4, rho value 0.229
  .04) and TIMP-2 (Figure 5, rho value 0.288, P 
009) and aneurysm size.
Examination by categorized size (Table 3) showed 
reased MMP-13 (Figure 6) in the 4.0- to 5.9-cm diam
ize range compared with the 3.9-cm group followed by a
eduction in the 6.0-cm size range. In addition, decreased
MP-1, MMP-3, and TIMP-2 were demonstrated in the
.0- to 5.9-cm diameter size range compared with the
ABLE 2. MMP and TIMP in BAV by ascending size
median [interquartile range])
<3.9 cm 4.0-5.9 cm >6.0 cm
AV Analyte (n  38) (n  44) (n  9)
ollagenases MMP-1 83 (103) 70 (57) 65 (38)
MMP-8 69 (77) 96 (90) 76 (97)
MMP-13 50 (133) 68 (116) 94 (95)
elatinases MMP-2 106 (67) 143 (85)* 125 (27)
MMP-9 45 (89) 52 (94) 53 (42)
ysins MMP-3 67 (81) 37 (60)* 91 (76)
MMP-7 85 (80) 82 (123) 57 (78)
embrane type MMP-14 75 (114) 38 (61)* 35 (77)
MMP-15 85 (34) 96 (69) 123 (18)
lastase MMP-12 74 (67) 79 (78) 101 (195)
nhibitors TIMP-1 72 (99) 68 (151) 36 (25)*
TIMP-2 80 (41) 79 (50) 83 (39)
TIMP-3 48 (77) 58 (65) 102 (158)
TIMP-4 79 (67) 75 (52) 105 (61)
MP, Matrix metalloproteinase; TIMP, tissue inhibitors of metalloprotein-
se; BAV, bicuspid aortic valve. *P 0.05 vs 3.9-cm group.
igure 4. Comparison of MMP-7 levels for BAV and TAV aneu-
ysms by aneurysm size. In the TAV cohort, MMP-7 was increased
n the large aneurysm group compared with the small aneurysm
roup. MMP, Matrix metalloproteinase; BAV, bicuspid aortic
alve; TAV, tricuspid aortic valve.
and Cardiovascular Surgery ● Volume 133, Number 4 1031
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1
A
CD3.9-cm group. MMP-7 was seen to be increased (Figu
n the in the 6.0-cm size range compared with the
3.9-cm group.
egression Analyses
egression analysis examining the affect of age on MMP
evels showed a positive effect on MMP-13 in the BAV
roup (P  .021). A positive correlation was observed
etween MMP-1 and presence of hypertension (P  .02)
igure 5. Comparison of TIMP-2 levels for BAV and TAV aneu-
ysms by aneurysm size. In the TAV cohort, TIMP-2 decreased in
he medium aneurysm group compared with the small aneurysm
roup. TIMP, tissue inhibitors of metalloproteinase; BAV, bicus-
id aortic valve; TAV, tricuspid aortic valve.
ABLE 3. MMP and TIMP in TAV by ascending size
median [interquartile range])
<3.9 cm 4.0-5.9 cm >6.0 cm
AV Analyte (n  38) (n  29) (n  17)
ollagenases MMP-1 83 (103) 51 (57)* 65 (52)
MMP-8 69 (77) 87 (91) 120 (68)
MMP-13 50 (133) 117 (345)* 30 (111)†
elatinases MMP-2 106 (67) 91 (42) 92 (33)
MMP-9 45 (89) 79 (107) 56 (101)
ysins MMP-3 67 (81) 38 (24)* 55 (58)
MMP-7 85 (80) 86 (91) 167 (223)*
embrane type MMP-14 75 (114) 95 (64) 80 (106)
MMP-15 85 (34) 74 (57) 89 (53)
lastase MMP-12 74 (67) 67 (62) 70 (73)
nhibitors TIMP-1 72 (99) 104 (176) 76 (56)
TIMP-2 80 (41) 50 (33)* 61 (49)
TIMP-3 48 (77) 49 (126) 58 (127)
TIMP-4 79 (67) 104 (81) 99 (91)
MP, Matrix metalloproteinase; TIMP, tissue inhibitors of metalloprotein-
se; TAV, tricuspid aortic valve. *P 0.05 vs 3.9-cm group. †P  .05 vs
.0-5.9-cm group.
032 The Journal of Thoracic and Cardiovascular Surgery ● Apr)
nly when the entire cohort of samples was considered as 1
roup. When aneurysm size was indexed by body surface
rea, a positive size correlation was found only for MMP-8
P  .04) in the BAV group. No significant relationships
ere observed between MMP levels and valve pathology.
iscussion
he congenitally bicuspid aortic valve is the most common con-
enital cardiovascular malformation, affecting 0.9% to 2% of the
eneral population.11 Congenital BAVs are prone to developm
f both stenosis and regurgitation and are associated with aortic
athology such as coarctation and dissection, in addition to an
ncreased incidence of ATAAs.11 Current hypotheses with regar
o BAV-related ATAA formation include genetic abnormalities in
he neural crest-origin cells in the ascending aorta and the flow
ypothesis, in which turbulent blood flow across the BAV results
n hemodynamic stress on the ascending aortic wall, especially the
ight anterolateral (outer) convexity. 11,12 Although the histopatho-
ogic description of the manifestations of BAV with respect to
TAAs is improving,12 the underlying biochemical basis f
hese structural changes within the extracellular matrix remains
oorly understood. It is now recognized that alterations in a
pecific extracellular matrix proteolytic cascade involving the
MPs and TIMPs occur in various cardiovascular disease states
uch as abdominal aortic aneurysms as well as ATAAs. 5,6 How-
ver, a comparative, comprehensive quantitation of MMPs and
IMPs that occur within ATAAs in BAV with respect to TAV
as not been performed. Accordingly, the present study measured
epresentative MMPs from each of the major classes of this
etalloprotease family, as well as all of the currently known
IMPs in a sample of ATAAs resected from patients with BAV
Figure 6. Comparison of MMP-13 levels for BAV and TAV aneu-
rysms by aneurysm size. MMP-13 was increased in the TAV
cohort for medium-sized aneurysms compared with the small
aneurysm group. The large group showed a significant decrease
in MMP-13 compared with the medium sized aneurysm group.
MMP, Matrix metalloproteinase; BAV, bicuspid aortic valve; TAV,
tricuspid aortic valve.
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A
CDnd TAV. When compared with reference control patients, the
nique findings from this study were that specific MMP and
IMP profiles emerged in the ATAAs from patients with BAV
ompared with the patients with TAV. For example, significantly
ncreased MMP-2 and decreased membrane type-1 MMP (MMP-
4) occurred in the ATAAs from patients with patients with BAV.
n contrast, the TAV aortic samples showed increased MMP-13
nd decreased TIMP-2. These findings, with respect to processing
f extracellular matrix constituents as well as other biologic sig-
aling molecules, would suggest that a unique proteolytic process
ccurs in the development of ATAAs in patients with BAV,
hich may hold future diagnostic and prognostic implications.
Several studies to date have compared MMP and TIMP
xpression in BAV versus TAV aortic samples.1-4 Fedak
nd colleagues1 reported increased MMP-2 in BAV aor
amples compared with TAV samples with no changes in
MP-9 between the 2 groups. Boyum and colleag2
emonstrated both increased MMP-2 and MMP-9 in BAV
amples, with no differences in TIMP-1 and TIMP-2 rela-
ive to TAV aortic tissue. Koullias and associates3 examined
alve tissue from patients with BAV and TAV, of which
alf of the population required a concomitant aortic proce-
ure. The results showed increased MMP-2 and MMP-9 in
he BAV tissue with nonsignificant trends toward increased
IMP-1 and TIMP-2 compared with the patients with TAV.
emaire and coworkers4 compared ATAA tissue from p-
ients with BAV and patients with TAV to control ascend-
ng aortic samples and found increased MMP-2 in the BAV
amples compared with TAV and control and increased
MP-9 in the TAV samples compared with BAV and
ontrol, with no differences in TIMP-1 and TIMP-2. The
esults mentioned earlier raise several points. First, of the
reater than 25 known MMPs and 4 TIMPs,13 the studies
entioned earlier provide a limited profile of MMP and
IMP types in BAV and TAV tissue. The present study
ontributes to the data described earlier by providing a more
omprehensive survey of the known MMP classes in addi-
ion to all 4 TIMPs. Second, there is disparity with regard to
he involvement of MMP-9 in the pathogenesis of these
ommon forms of ATAA, in contrast to abdominal aortic
neurysms where MMP-9 is considered to be very impor-
ant.5,6 The present study showed little change in MMP-
ither BAV or TAV tissue. Third, each study discussed
arlier showed an increase in MMP-2 in the BAV group,
hich is also supported by the findings of the present study.
inally, in contrast to the previous studies, the larger sample
ize of this study allowed comparison of numerous MMPs
nd TIMPs by increasing aneurysm size.
MPs
or BAV samples, the significant findings of this study were
ncreased MMP-2 and decreased MMP-14 overall, with
hese results seen particularly in the 4.0- to 5.9-cm size M
The Journal of Thoracicange. MMP-2, or gelatinase A, is synthesized by resident
ells in the aortic wall such as fibroblasts, smooth muscle
ells, and endothelial cells.13 It is not released by infla-
atory cells such as neutrophils and macrophages, and
ecent work has demonstrated a reduced inflammatory in-
ltrate seen in BAV-associated ATAAs compared with
AV-associated ATAAs, consistent with these observa-
ions.4 MMP-2, in addition to its elastolytic properties, 
leaves numerous collagen subtypes (I-V, XI), laminin, and
brillin-1.14,15 It has recently been shown that extracellu
atrix remodeling and dilatation of the ascending aorta in
atients with BAV occurs in an asymmetrical fashion,
hich is most pronounced in the right anterolateral aspect
convexity).12 The study by Della Corte and colleague12
emonstrated a reduction in collagens I and III in addition to
aminin in the outer convexity compared with the inner
oncavity of BAV-associated ATAAs, consistent with
MP-2 activity. Further, Fedak and associates1 howed
ecreased fibrillin-1 in BAV-associated ATAA tissue con-
istent with the finding of increased MMP-2 observed in this
opulation. In addition, it is well described that MMP-2 is
ctivated in response to turbulent flow and shear stresses
uch as those seen across a BAV and disproportionally in
he outer curvature of the ascending aorta.16 However, the
resent study showed no statistical correlation between
alve pathology and aneurysm formation in either valve
roup, suggesting that the turbulent flow relationship may
e 1 of many factors acting in concert to form aneurysms.
With regard to MMP-2 activation, it is interesting that
MP-14 is decreased in the setting of an increase of
MP-2 in this population. One major function of MMP-14
s the activation of MMP-2 by a mechanism involving
IMP-2.17,18 Although not quantified, the immunoblottin
esults (Figure 1) showed an increase in the active 
66 kd) of MMP-2 in BAV-associated ATAA tissue, sug-
esting increased MMP-2 activity. When taken together
ith the observed decrease in MMP-14, this suggests that an
lternative mechanism of MMP-2 activation is operational,
finding that warrants further investigation.
For the TAV samples, perhaps the most significant find-
ng is that of increased MMP-13 in the 4.0- to 5.9-cm size
ange, with a decrease in this species with larger aneurysm
ize. MMP-13, or collagenase-3, is a powerful proteinase
roduced by native cells in the aortic wall, and its expres-
ion is strictly controlled under normal physiologic con-
itions. It has a broad substrate specificity including
any collagen types (I-IV, IX, X, XIV), tenascin C,
bronectin, aggrecan, versican, and osteonectin.18 In ad-
ition, MMP-13 can inactivate chemokines, such as
onocyte chemoattractant protein-3 and stromal cell-
erived factor-1.19 MMP-13 also appears to be involv
n the activation of pro-transforming growth factor-3.MP-13 expression is also detected in pathologic condi-
and Cardiovascular Surgery ● Volume 133, Number 4 1033
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CDions that are characterized by the destruction of normal
ollagen-containing tissue architecture, including abdomi-
al aortic aneurysms.20 The unique finding of increas
MP-13 in the TAV group in this study is consistent with
xtracellular matrix destruction and perhaps an active
xpansion phase in medium-sized ATAAs. As the aneu-
ysm grows further, there may be a sufficient decline of
esident cells (by senescence and apoptosis) to decrease
he amount of MMP-13 produced, explaining the decline
n MMP-13 demonstrated for larger aneurysm sizes. In
ddition, regression analysis showed a positive correla-
ion between MMP-13 and age. Previous work has shown
hat tissue MMP levels are age sensitive,13,14 and the
ssociative result shown in the present study suggests
hat MMP-13 may be even more important for aneurysm
ormation in older patients.
Another interesting finding with the TAV group is the
emonstration of increased MMP-7 in large aneurysms.
MP-7, or matrilysin, is a small-molecular-weight MMP
laborated by many cell types, both constitutive and inflam-
atory. It serves numerous functions including extracellular
atrix degradation (elastin, type IV collagen, fibronectin,
itronectin, aggregan, and proteoglycans), MMP (1, 2,
9) activation, and regulation of bioactive molecules con-
rolling inflammation, cell proliferation, apoptosis, invasion,
nd angiogenesis.21 Of potential relevance to the prese
tudy is the ability of MMP-7 to cleave tumor necrosis
actor (TNF)- precursor to release soluble TNF-, which,
hrough binding to TNF-receptor 1, may increase apoptosis.
n abdominal aortic aneurysms, increased MMP-7 levels
ave been demonstrated only in the aneurysm wall and not
uminal thrombus, suggesting that MMP-7 was elaborated
ore likely by resident cells within the aortic wall than by
nflammatory cells.22,23 As such, MMP-7 may play an -
ortant late role on aneurysm progression though promotion
f continued cellular attrition within the aortic wall.
In general, the derangements described earlier occurred
or MMPs that are constitutively expressed by cells resident
ithin the aortic wall (fibroblasts, smooth muscle cells).
here appears, at least from this analysis, to be less of a
roteolytic contribution from those MMPs elaborated from
nflammatory cells (eg, MMP-8, MMP-9, MMP-12) for the
scending aorta than that seen in the abdominal aorta.5,24,25
t is possible that in response to pathologic stimuli, the
esident cells undergo a pathologic transformation, resulting
n increased MMP synthesis and release with increasing
neurysm size. Additional studies are required to address
his hypothesis.
IMPs
rimary endogenous control of MMP activity is maintained
hrough 4 TIMPs. Each member of the TIMP family exhib-
ts a distinct pattern of affinity for particular MMPs through r
034 The Journal of Thoracic and Cardiovascular Surgery ● Apr reversible, 1:1 interaction,7 and stoichiometry shifts be-
ween MMPs and TIMPs have been shown to favor abdom-
nal aortic aneurysm formation.6,12 In addition, TIMPs hav
number of other effects including activation of other
MPs, potentiation of growth factors, and instigation or
uppression of apoptosis.7 In the present study, a compl
urvey of all 4 TIMPs was undertaken including TIMP-1,
ighly expressed in the aorta,6,12 and the cardiovascula
ystem–specific TIMP-4.26 In the present study, TIMP
as decreased in the BAV group in the 6.0-cm size range
nd TIMP-2 was decreased in the TAV group in the 4.0- to
.9-cm size range. Decreased TIMPs in the setting of in-
reased MMPs as shown earlier could represent a stoichi-
metry shift of proteolytic activity versus endogenous inhi-
ition favoring extracellular matrix breakdown and ATAA
rowth.
linical Significance
he present study identified specific and different MMP and
IMP species produced in tissue of BAV- versus TAV-
ssociated ATAAs. These species may provide important
herapeutic targets in that tailored inhibitory strategies
imed at these MMPs may decrease or halt ATAA forma-
ion while minimizing the untoward side effect profiles
ypically associated with global MMP inhibition. Also,
ovel imaging or blood-testing techniques may be devel-
ped in which specific MMP imaging within the aorta may
e used for diagnostic and prognostic assessment. For ex-
mple, in the TAV group, imaging or plasma testing show-
ng increased MMP-13 could indicate a medium-sized
TAA in a growth phase, and the later emergence of
MP-7 could then indicate a more mature, larger-sized
TAA with a different expansion rate.
Because this study was performed on resected aortic
pecimens at the time of surgery, inherent limitations exist.
irst, it is unclear whether the MMP and TIMP profiles
easured are reflective of a specific stage in aneurysm
rogression or represent a summary of multiple phases. As
tated earlier, further studies are required to develop other
echniques of aneurysm characterization such as specific
MP plasma assays or imaging modalities to more care-
ully address this limitation. In addition, the potential for
egional aortic heterogeneity implies that MMP and TIMP
rofiles seen in the ascending aorta may be different from
he aortic arch or descending thoracic aorta and hence are
ot translatable. Also important is that caution must be
xercised in extrapolating these MMP measurement results
o true matrix-degrading activity and thus a more direct
ssessment of activity is required. By strict measurement
riteria, some of the samples obtained were not from aortas
hat would truly be considered to be aneurysmal. However,
ssessment of these patients is also important because this
epresents the early stages of aneurysm formation where an
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A
CDarly intervention may reduce, arrest, or reverse the dilata-
ion process. Although different MMP cassettes were dem-
nstrated for BAV- and TAV-associated ATAA tissue, a
rue cause-effect relationship between these changes and
neurysm expansion was not demonstrated and thus further
tudies are warranted. Comparison of aneurysmal aorta to
djacent nondilated aorta could be helpful in this regard.
inally, careful examination of the inner and outer curvature
f the aneurysm wall is required to define regional MMP
nd TIMP profiles as they relate to disparities in extracel-
ular matrix remodeling within the aneurysm.
Nevertheless, the results from the present study imply
hat a unique and differential extracellular matrix proteo-
ytic signature exists in within the aorta of patients with
AV as opposed to patients with TAV with ascending
ortic aneurysm disease and suggests that these disease
rocesses do not follow a common etiology.
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MP-1 IM35L 1:2500 Oncogene
MP-3 IM36L 1:5000 Oncogene
MP-7 PC492 1:2500 Oncogene
MP-8 358-100 1:2500 Biovision
MP-12 RP1-MMP12 1:2500 Triple Point
MP-13 RP3-MMP13 1:2500 Triple Point
MP-14 AB815 1:5000 Chemicon
MP-15 RP2-MMP-15 1:2500 Triple Point
IMP-1 OPA1-08512 1:2500 Affinity
IMP-2 IM11L 1:2500 Oncogene
IMP-3 AB802 1:1000 Chemicon
IMP-4 AB816 1:2500 Chemicon
MP, Matrix metalloproteinase; TIMP, tissue inhibitors of
etalloproteinase. *Company information: Oncogene, Boston, Mass; Bio-
ision, Mountain View, Calif; Triple Point Biologics, Forest Green, Ore;
hemicon, Temecula, Calif; Affinity Bioreagents, Golden, Colo.
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CDiscussion
r John A. Kern (Charlottesville, Va). John, that was a very nice
tudy that gives us more insight into the molecular biology of
scending aortic aneurysm pathology. As you detailed in your
anuscript, but not so much here because of time constraints, your
esults really parallel those of others. However, your study goes a
it further in showing us various activity profiles even among
neurysms of different sizes, which is quite interesting.
The main questions I have, to bring this into some clinical
ppreciation, is what does this study really do in furthering our
nderstanding of the natural history of ascending aortic aneurysms,
nd will findings such as these ultimately change the way we
pproach aneurysms, particularly with respect to timing of repair?
I also have a few nuts-and-bolts questions. The patients in the
ontrol group were quite a bit younger than those in the other
roups, and it makes us wonder about the biology of MMPs in
eneral, so could you just talk a bit about that. Also, your findings
ay have a genetic basis. Did you see any differences in profiles
ith respect to gender?
In addition, there is potentially a lot of differing medical
herapy in these patients, so I’m wondering, as the patients weren’t
ontrolled for things like antihypertensive therapy and antilipid
herapy, could those factors have had an impact on your results?
And last, obviously what we’re all interested in is trying to
gure out which patients are getting ready to have an aortic
atastrophe. So is there any way we can use these results—in other
ords, are any of these molecules considered such acute phase–
ype reactants, that we could somehow formulate an assay,
hether it be a serum assay or an imaging test, that we could use
o find those patients who are getting ready to become unstable?
nd then, if so, could we use these concepts to formulate some
orm of therapy, whether it be through conventional techniques or
ndovascular techniques?
Dr John S. Ikonomidis (Charleston, SC). Thank you, Dr Kern,
or raising those very pertinent issues. In answer to your overall
uestion, I think that we continue to further our knowledge about
iology of ATAA disease; specifically, we are starting to tease out
olecular pathways and effectors not just for 1 aneurysm type but
ow among various pathologic types.
I think that the present study adds to previous studies in the
ense that we have examined a broader range of MMPs and TIMPs
nd provided, perhaps, a larger profile. And in addition, we have
ad somewhat of a larger sample size, which allowed some cor-
elations to be made to aneurysm size, although I should preface
hat by saying that Dr Fedak has already demonstrated at the P 
05 level an association between MMP-2 and bicuspid ascending
ortic aneurysms.
As far as age is concerned, there is no doubt that age within the
ardiovascular system has an effect on MMP biology. And this is
confounding factor in this study that would be difficult to
emove. This point is offset, to some extent, by the fact that we t
036 The Journal of Thoracic and Cardiovascular Surgery ● Aprere able to examine specific aneurysm types by size within each
roup.
MMPs, in general, are not considered acute-phase reactants.
hey are extremely tightly regulated molecules that are active in
oth healthy and diseased states. In our animal model, we saw
pregulation of MMP-2 and MMP-9 within approximately 72
ours of an aneurysm stimulus.
As far as gender is concerned, we did analyze these results by
ender and found no statistical differences.
There are certain medical therapies that would modify MMP
ctivity. For example, treatment of these patients with beta-
lockers and the resultant decrease in shear stresses and dP/dt
ould decrease certain MMPs that are stress dependent, partic-
larly MMP-2. This could have a significant impact in therapy
or these aneurysms, much the same as there is a salutary effect
n Marfan’s syndrome.
None of these aneurysms came from patients who had an
mpending catastrophe, so I’m not able to provide profiles to you
bout those particular patients; however, development of specific
lasma or radiologic imaging strategies may allow us to charac-
erize the MMP profiles over time such that with further study, we
ay be able to identify a specific MMP and TIMP cassette that
ay indicate an impending rupture or a change in the character of
he aneurysm. And to that end, enzyme-linked immunosorbent
ssay tests are already being developed for following MMPs and
IMPs such as MMP-9, MMP-2, and TIMP-1 post–myocardial
nfarction, such that these may also be an option for following
atients with thoracic aortic aneurysm disease.
Furthermore, radiolabeled short-acting inhibitors, either global
r specific, bind within the cardiovascular system and can be
maged. We may be able to use these for serial imaging to follow
ither global MMP activity or specific MMPs as we tease out the
ifferent MMP profiles within the different aneurysm groups.
And finally, how can we make this work for us? These data
ay help us with diagnosis and prognostication. Also, novel
herapeutic strategies could include development of specific MMP
nhibitors that target 1 MMP or a specific subgroup of MMPs out
f the 26 known species, thus reducing the side-effect profiles that
re classically seen with global MMP inhibition. Obviously, gene
herapy is also a possibility.
Endovascular stent grafting is a very hot therapeutic modality
ight now; but a potential problem with this treatment modality is
hat the stent-grafted aorta likely continues to remodel. Thus, over
ime, the stent graft may fail through continued remodeling of the
neurysm and aorta both proximal and distal to the stent-graft. It
herefore may be valuable to place MMP inhibitors within the
abric of the aneurysm to arrest remodeling and thus increase the
ongevity of the stent-graft repair.
Dr Doosang Kim (Seoul, Korea). My question is about the
ocation of the sample site. Where is the most common location of
he sample site?
Dr Ikonomidis. The sample site was taken at the point where
he aneurysm was largest by inspection at the time of resection.
il 2007
